Codex DNA, Inc. (DNAY)
|Net Income (ttm)||-21.57M|
|Trading Day||June 18|
|Day's Range||17.13 - 21.75|
|52-Week Range||17.13 - 21.75|
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (“Codex DNA”), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today ...
Codex DNA, Inc. (“Codex DNA”), creators of the BioXp™ system, a fully automated benchtop instrument that...
Codex DNA, Inc. has filed to go public with an IPO on the NASDAQ.
Codex DNA is a leading synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. A key part of our solution is our BioXp system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease-of-use and hands-free automation. We believe our BioXp system can democratize synthetic biology by simplifying the process of building DNA and mR... [Read more...]
|IPO Date |
Jun 18, 2021
Todd R. Nelson
|Stock Exchange |
|Ticker Symbol |
In 2020, Codex DNA's revenue was $6.58 million, an increase of 36.86% compared to the previous year's $4.81 million. Losses were -$18.01 million, 116.9% more than in 2019.